Literature DB >> 18217211

Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases.

Kazuhiro Miwa1, Masayuki Matsuo, Jun Shinoda, Naoki Oka, Takayuki Kato, Ayumi Okumura, Tatsuya Ueda, Kazutoshi Yokoyama, Jitsuhiro Yamada, Hirohito Yano, Shinichi Yoshimura, Toru Iwama.   

Abstract

We performed hypofractionated high-dose irradiation of a patient's residual glioblastoma multiforme using a simultaneous integrated boost (SIB) technique with helical tomotherapy system (HT) planning. The gross tumor volume (GTV)-1 was defined as the area of intensive (11)C-methionine (MET) uptake and GTV-2 was defined as the area of moderate MET uptake. The planning target volume (PTV)-1 encompassed GTV-1 plus a 5 mm margin, and PTV-2 encompassed GTV-2 plus a 2 mm margin. SIB with HT was performed in eight fractions, planning the dose for GTV-1 at 68 Gy (biologically effective dose: BED = 126 Gy), PTV-1 at 56 Gy (BED = 95 Gy), and PTV-2 at 40 Gy (BED = 60 Gy). In each of the target areas, the uptake value on (11)C-methionine positron emission tomography (MET-PET) was considerably decreased following SIB, although no remarkable changes were demonstrated on magnetic resonance imaging (MRI). These cases demonstrate that SIB with HT planning using MET-PET offers excellent target coverage and uniformity. In addition, SIB with HT planning using MET-PET is organ sparing and MET-PET has great efficacy for monitoring treatment response after SIB. To more clearly define the impact of SIB with HT planning using MET-PET, further investigations are required.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18217211     DOI: 10.1007/s11060-008-9519-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

Review 1.  Helical tomotherapy: an innovative technology and approach to radiation therapy.

Authors:  James S Welsh; Rakesh R Patel; Mark A Ritter; Paul M Harari; T Rockwell Mackie; Minesh P Mehta
Journal:  Technol Cancer Res Treat       Date:  2002-08

2.  L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.

Authors:  Anca-Ligia Grosu; Wolfgang A Weber; Eva Riedel; Branislav Jeremic; Carsten Nieder; Martina Franz; Hartmut Gumprecht; Ruprecht Jaeger; Markus Schwaiger; Michael Molls
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

3.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

4.  Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures.

Authors:  Benoît Pirotte; Serge Goldman; Olivier Dewitte; Nicolas Massager; David Wikler; Florence Lefranc; Nordeyn Oulad Ben Taib; Sandrine Rorive; Philippe David; Jacques Brotchi; Marc Levivier
Journal:  J Neurosurg       Date:  2006-02       Impact factor: 5.115

5.  Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.

Authors:  T Ogawa; I Kanno; F Shishido; A Inugami; S Higano; H Fujita; M Murakami; K Uemura; N Yasui; K Mineura
Journal:  Acta Radiol       Date:  1991-05       Impact factor: 1.990

6.  Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.

Authors:  Ashwatha Narayana; Josh Yamada; Sean Berry; Priti Shah; Margie Hunt; Philip H Gutin; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-01       Impact factor: 7.038

7.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

8.  Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma.

Authors:  Tadashi Nariai; Yoji Tanaka; Hiroaki Wakimoto; Masaru Aoyagi; Masashi Tamaki; Kiichi Ishiwata; Michio Senda; Kenji Ishii; Kimiyoshi Hirakawa; Kikuo Ohno
Journal:  J Neurosurg       Date:  2005-09       Impact factor: 5.115

9.  Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience.

Authors:  Anca-Ligia Grosu; Rainer Lachner; Nicole Wiedenmann; Sibylle Stärk; Reinhard Thamm; Peter Kneschaurek; Markus Schwaiger; Michael Molls; Wolfgang A Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

10.  Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.

Authors:  Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

View more
  9 in total

1.  Corticospinal tract-sparing intensity-modulated radiotherapy treatment planning.

Authors:  Hiroshi Igaki; Akira Sakumi; Akitake Mukasa; Kuniaki Saito; Akira Kunimatsu; Yoshitaka Masutani; Shunya Hanakita; Kenji Ino; Akihiro Haga; Keiichi Nakagawa; Kuni Ohtomo
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

2.  Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.

Authors:  Shingo Yonezawa; Kazuhiro Miwa; Jun Shinoda; Yuichi Nomura; Yoshitaka Asano; Noriyuki Nakayama; Naoyuki Ohe; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

3.  Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme.

Authors:  Kazuhiro Miwa; Masayuki Matsuo; Shin-ichi Ogawa; Jun Shinoda; Yoshitaka Asano; Takeshi Ito; Kazutoshi Yokoyama; Jitsuhiro Yamada; Hirohito Yano; Toru Iwama
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

4.  Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.

Authors:  Kazuhiro Miwa; Masayuki Matsuo; Shin-ichi Ogawa; Jun Shinoda; Kazutoshi Yokoyama; Jitsuhiro Yamada; Hirohito Yano; Toru Iwama
Journal:  Radiat Oncol       Date:  2014-08-14       Impact factor: 3.481

5.  Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab.

Authors:  Hirohito Yano; Noriyuki Nakayama; Kasumi Morimitsu; Manabu Futamura; Naoyuki Ohe; Kazuhiro Miwa; Jun Shinoda; Toru Iwama
Journal:  Clin Med Insights Oncol       Date:  2014-12-09

6.  Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).

Authors:  Oliver Oehlke; Michael Mix; Erika Graf; Tanja Schimek-Jasch; Ursula Nestle; Irina Götz; Sabine Schneider-Fuchs; Astrid Weyerbrock; Irina Mader; Brigitta G Baumert; Susan C Short; Philipp T Meyer; Wolfgang A Weber; Anca-Ligia Grosu
Journal:  BMC Cancer       Date:  2016-10-05       Impact factor: 4.430

Review 7.  Amino acid PET and MR perfusion imaging in brain tumours.

Authors:  Christian P Filss; Francesco Cicone; Nadim Jon Shah; Norbert Galldiks; Karl-Josef Langen
Journal:  Clin Transl Imaging       Date:  2017-03-13

8.  [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.

Authors:  Damien C Weber; Thomas Zilli; Franz Buchegger; Nathalie Casanova; Guy Haller; Michel Rouzaud; Philippe Nouet; Giovanna Dipasquale; Osman Ratib; Habib Zaidi; Hansjorg Vees; Raymond Miralbell
Journal:  Radiat Oncol       Date:  2008-12-24       Impact factor: 3.481

Review 9.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.